Drugs / Volrustomig
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT05821231 | Dec 2023 → Sep 2026 | soft tissue sarcoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 1 | NCT05685472 | Dec 2022 → Aug 2023 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04686305 | Mar 2021 → Jun 2027 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04612751 | Feb 2021 → May 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04522323 | Aug 2020 → Sep 2025 overdue | renal cell carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03819465 | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03530397 | Apr 2018 → Jul 2025 overdue | — | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07065630 | Oct 2025 → Aug 2029 expected | head and neck squamous cell carcinoma, human papilloma virus infection | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT05888857 | Sep 2025 → Mar 2026 overdue | — | Institut Bergonié | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06943833 | Mar 2025 → Mar 2028 expected | cervical cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06792695 | Mar 2025 → Jun 2027 expected | colorectal cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06448754 | Aug 2024 → Jul 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06535607 | Aug 2024 → Nov 2028 expected | head and neck squamous cell carcinoma, malignant mesothelioma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06152523 | Dec 2023 → Dec 2028 | colorectal cancer | Assistance Publique - Hôpitaux de Paris | Withdrawn | No outcome recorded |
| Phase 2 | NCT05775159 | Apr 2023 → Oct 2026 expected | biliary tract cancer, hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05702229 | Jan 2023 → Nov 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT05061550 | Apr 2022 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT03741426 | Jul 2020 → Dec 2027 expected | renal cell carcinoma | CCTU- Cancer Theme | Recruiting | No outcome recorded |
| Phase 2 | NCT04379596 | Jun 2020 → Jun 2027 expected | gastric cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07000149 | Jul 2025 → Feb 2030 expected | clear cell renal carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06129864 | Dec 2023 → Apr 2030 expected | head and neck squamous cell carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06097728 | Nov 2023 → Nov 2028 expected | pleural mesothelioma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05984277 | Oct 2023 → Aug 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06079671 | Sep 2023 → Nov 2027 expected | cervical cancer | AstraZeneca | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05489211 Background | Sep 2022 → Oct 2027 expected | biliary tract cancer, castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer +3 | AstraZeneca | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-17 | Alexion Pharmaceuticals, Inc. | Results Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer astrazeneca.com ↗
The IDMC concluded that the volrustomig combination was unlikely to meet either of the dual primary endpoints of progression-free survival (PFS) or overall survival (OS) in the primary analysis population of patients with PD-L1 negative tumours (<1%) versus the comparator arm. |
| 2018-04-04 | AstraZeneca | Results AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC astrazeneca.com ↗
MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-17 | Alexion Pharmaceuticals, Inc. | Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer astrazeneca.com ↗ |
| 2024-10-02 | Arcus Biosciences, Inc. | Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma arcusbio.com ↗ |
| 2018-04-04 | AstraZeneca | AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Volrustomig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05702229 ↗ |
| Known as | MEDI5752 | “This is a phase II, single-arm open-label study to explore the efficacy and safety of volrustomig (MEDI5752) in women with high-risk locally advanced cervical cancer...” NCT06943833 ↗8“These data justify the development of bispecific monoclonal antibodies targeting both PD1 and CTLA4 such as MEDI5752.” NCT06152523 ↗ |
| Action | Inhibit | “anti PD-1” NCT05702229 ↗ |
| Modality | Monoclonal antibody | “an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion” NCT05702229 ↗ |
| Route | Intravenous | “MEDI5752 IV” NCT03819465 ↗ |